Researchers at Southern Ural State University in Chelyabinsk have developed and examined new platinum complex compounds that may become drugs for cancer chemotherapy, HIV treatment, and atypical pneumonia. The information came through TASS reports.
The university’s press service highlighted that these platinum complexes show distinctive properties. Scientists observed reduced toxicity compared with some conventional chemotherapeutic agents and noted a potential to shield essential human enzymes that chemotherapies can target. This protective aspect could help strengthen the body’s natural defenses during cancer treatment, potentially improving patient tolerability and outcomes over time.
In addition, the findings suggest these compounds might play a role in fighting viral infections, including HIV and SARS. The research underscores the possibility that platinum-based agents could contribute to broader therapeutic strategies against challenging viral diseases while maintaining a favorable safety profile.
Earlier work indicated collaborations between Russian scientists and international partners in the search for effective HIV remedies. International teams have pursued innovative compounds to address the virus, aiming to broaden the arsenal of antiviral options beyond existing therapies.
One example of these collaborative efforts involves the Federal Research Center for Biotechnology of the Russian Academy of Sciences, working alongside American and Italian colleagues to explore new chemical structures with anti-HIV potential. The team has proposed a novel class of compounds, including N-phenyl derivatives linked to triazole-based amines, as part of ongoing efforts to identify agents with improved efficacy and safety for HIV management.